Tags

Type your tag names separated by a space and hit enter

Increased ω-3 polyunsaturated fatty acid/arachidonic acid ratios and upregulation of signaling mediator in individuals with autism spectrum disorders.
Life Sci. 2016 Jan 15; 145:205-12.LS

Abstract

AIMS

The investigation of links between the ratio of omega-3/omega-6 PUFAs and neuronal signaling is a research priority in autism spectrum disorders (ASD).

MAIN METHODS

We examine the relationships between the plasma ratios of docosahexaenoid acid (DHA)/arachidonic acid (AA) and eicopentaenoic acid (EPA)/AA and biomarkers of AA-related signaling mediators such as ceruloplasmin, transferrin and superoxide dismutase, in the behavioral symptoms of 28 individuals with ASD (mean age 13.5±4.6years) and 21 age- and gender-matched normal healthy controls (mean age 13.9±5.7years). Behavioral symptoms were assessed using the Aberrant Behavior Checklists (ABC). We conducted controlling for dietary intake and assessed the dietary intake of nutrients.

KEY FINDINGS

There were no significant differences in intake of nutrients such as omega-3 and omega-6 PUFAs, saturated and unsaturated fatty acid, DHA, AA, iron and copper. Plasma EPA, DHA, and arachidic acid levels, and plasma DHA/AA and EPA/AA ratios were significantly higher, while plasma AA and adrenic acid were significantly lower in the 28 individuals with ASD than in the 21 normal controls. The ABC scores were significantly higher in the ASD group compared to the control group. The plasma ceruloplasmin levels in the ASD group were significantly reduced compared to those in the control group.

SIGNIFICANCE

Increased plasma DHA/AA and EPA/AA ratios may be related to low plasma levels of ceruloplasmin which has neuroprotective properties. Reduced plasma ceruloplasmin levels may diminish the protective capacity against brain damage, and may contribute to the pathophysiology of behavioral symptoms in individuals with ASD.

Authors+Show Affiliations

Research Institute of Pervasive Developmental Disorders, Ashiya University, 13-22 Rokurokusocho, Ashiya 659-8511, Hyogo, Japan. Electronic address: yui16@bell.ocn.ne.jp.Department of Pediatrics, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu 321-0293, Tochigi, Japan.Department of Drug Evaluation and Informatics, School of Pharmaceutical Science, University of Shizuoka., 52-1 Yada, Shizuoka 422-8526, Japan.Department of Drug Evaluation and Informatics, School of Pharmaceutical Science, University of Shizuoka., 52-1 Yada, Shizuoka 422-8526, Japan.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26724495

Citation

Yui, Kunio, et al. "Increased Ω-3 Polyunsaturated Fatty Acid/arachidonic Acid Ratios and Upregulation of Signaling Mediator in Individuals With Autism Spectrum Disorders." Life Sciences, vol. 145, 2016, pp. 205-12.
Yui K, Imataka G, Kawasak Y, et al. Increased ω-3 polyunsaturated fatty acid/arachidonic acid ratios and upregulation of signaling mediator in individuals with autism spectrum disorders. Life Sci. 2016;145:205-12.
Yui, K., Imataka, G., Kawasak, Y., & Yamada, H. (2016). Increased ω-3 polyunsaturated fatty acid/arachidonic acid ratios and upregulation of signaling mediator in individuals with autism spectrum disorders. Life Sciences, 145, 205-12. https://doi.org/10.1016/j.lfs.2015.12.039
Yui K, et al. Increased Ω-3 Polyunsaturated Fatty Acid/arachidonic Acid Ratios and Upregulation of Signaling Mediator in Individuals With Autism Spectrum Disorders. Life Sci. 2016 Jan 15;145:205-12. PubMed PMID: 26724495.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased ω-3 polyunsaturated fatty acid/arachidonic acid ratios and upregulation of signaling mediator in individuals with autism spectrum disorders. AU - Yui,Kunio, AU - Imataka,George, AU - Kawasak,Yohei, AU - Yamada,Hiroshi, Y1 - 2015/12/24/ PY - 2015/07/27/received PY - 2015/11/15/revised PY - 2015/12/22/accepted PY - 2016/1/3/entrez PY - 2016/1/3/pubmed PY - 2016/6/14/medline KW - Arachidonic acid KW - Autism spectrum disorders KW - Ceruloplasmin KW - Competitive interaction KW - Omega-3 polyunsaturated fatty acids KW - Signaling mediator SP - 205 EP - 12 JF - Life sciences JO - Life Sci. VL - 145 N2 - AIMS: The investigation of links between the ratio of omega-3/omega-6 PUFAs and neuronal signaling is a research priority in autism spectrum disorders (ASD). MAIN METHODS: We examine the relationships between the plasma ratios of docosahexaenoid acid (DHA)/arachidonic acid (AA) and eicopentaenoic acid (EPA)/AA and biomarkers of AA-related signaling mediators such as ceruloplasmin, transferrin and superoxide dismutase, in the behavioral symptoms of 28 individuals with ASD (mean age 13.5±4.6years) and 21 age- and gender-matched normal healthy controls (mean age 13.9±5.7years). Behavioral symptoms were assessed using the Aberrant Behavior Checklists (ABC). We conducted controlling for dietary intake and assessed the dietary intake of nutrients. KEY FINDINGS: There were no significant differences in intake of nutrients such as omega-3 and omega-6 PUFAs, saturated and unsaturated fatty acid, DHA, AA, iron and copper. Plasma EPA, DHA, and arachidic acid levels, and plasma DHA/AA and EPA/AA ratios were significantly higher, while plasma AA and adrenic acid were significantly lower in the 28 individuals with ASD than in the 21 normal controls. The ABC scores were significantly higher in the ASD group compared to the control group. The plasma ceruloplasmin levels in the ASD group were significantly reduced compared to those in the control group. SIGNIFICANCE: Increased plasma DHA/AA and EPA/AA ratios may be related to low plasma levels of ceruloplasmin which has neuroprotective properties. Reduced plasma ceruloplasmin levels may diminish the protective capacity against brain damage, and may contribute to the pathophysiology of behavioral symptoms in individuals with ASD. SN - 1879-0631 UR - https://www.unboundmedicine.com/medline/citation/26724495/Increased_ω_3_polyunsaturated_fatty_acid/arachidonic_acid_ratios_and_upregulation_of_signaling_mediator_in_individuals_with_autism_spectrum_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0024-3205(15)30132-6 DB - PRIME DP - Unbound Medicine ER -